New drug combo targets advanced prostate cancer in early trial

NCT ID NCT06095089

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 21 times

Summary

This early-stage study is testing two experimental drugs (JNJ-87189401 and JNJ-78278343) together in people with advanced prostate cancer. The main goals are to find the best dose and check for side effects. About 250 participants will take part in this research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre Leon Berard
RECRUITING

Lyon, 69008, France
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States
Institut Gustave Roussy
RECRUITING

Villejuif, 94800, France
South Texas Accelerated Research Therapeutics, LLC (START)
RECRUITING

San Antonio, Texas, 78229, United States
Tennessee Oncology
RECRUITING

Nashville, Tennessee, 37203, United States
University of Colorado Anschutz Medical Campus
RECRUITING

Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED PROSTATE CANCER